Background; Ecteinascidin (ET-743) is a marine derived compound with an interesting preclinical profile currently completing phase I clinical trials. The present study was undertaken to compare the toxicity of different schedules of ET-743 against human hemopoietic progenitors and tumour cell lines.
Introduction
As a consequence of improvements in the technique for collecting living material from the sea, a number of compounds with anti-tumour properties have recently been isolated from marine organisms [1] . Ecteinascidin, isolated from Ecteinascidia turbinata, a tunicate found in the Caribbean Sea, is one of these compounds. Its structure comprises three tetrahydroisoquinolone systems, the condensation of which results in the formation of an active carbinolamine functional group [2] .
In vitro studies have demonstrated activity at nanomolar concentrations against a number of solid tumour cell lines, including melanoma, NSCLC, ovarian, renal, prostate and breast cancers and incomplete cross-resistance with several standard chemotherapeutic agents against tumors in human cloning assay [3] ; in vitro studies have also demonstrated that a continuous 24-hour exposure is more active than a single one-hour exposure [4] .
In murine xenografts significant antitumour activity was also shown in melanoma, NSCLC, ovarian and breast cancers, using both early-and advanced-stage models [5] . In some cases this activity was superior to that of cytotoxic drugs such as ifosfamide and cisplatin with established clinical roles in these tumors [6, 7] .
The mode of action of ET-743 includes the formation of covalent adducts at the Nj position of guanine in the minor groove of DNA by involving the reactive carbinolamine group [2, 8] .In addition, at relatively high concentrations, ET-743 causes disorganisation of microtubule filaments. These effects result in a cell cycle block in late S and G 2 M phases [9] . An interaction of ET-743 with nuclear proteins/translation factors was also suggested [10] .
Preclinical studies have shown hematologic and liver toxicity to be dose-limiting in mice, rats, dogs and monkeys [7] . Because the in vitro data demonstrated a relationship between exposure time and antitumour activity [4] , and toxicology results indicated that the incidence and severity of toxicity might be related to plasma concentrations, schedules of repeated or continuous exposures were selected for phase I evaluations. Therefore daily x 5 and 24-hour continuous infusion schedules were tested, and an i.v. one-hour study as the shorter infusion was assessed.
The aim of this work was to define the toxicity on hemopoietic cells of each schedule and to compare it to the cytotoxicity observed in different tumour cell lines. Human cord blood cells (hCB) have been shown to give results comparable to human bone marrow cells when used for hematotoxicology experiments [11] [12] [13] , and were therefore used as source of hematopoietic precursors.
Materials and methods
Preparation of drug and hemopoietic cells ET-743 was provided by PharmaMar (Madrid, Spain) as a dry powder, to be reconstituted with water, then diluted with medium to a concentrated stock solution and kept in aliquots at -80 °C. ET-743 solutions were prepared fresh before each experiment to avoid degradation.
Human cord blood (hCB) was obtained during the third phase of delivery by opening the umbilical cord clamp and allowing the blood to flow into a sterile heparinized 50 ml test tube. Samples were stored at room temperature and processed within 48 hours. Cells were separated by density centrifugation on a Ficoll gradient to obtain mononuclear cells (MNC) which were then adherent-cell depleted by overnight incubation in 20% foetal calf serum (FCS) in Iscove's modified Dulbecco medium (IMDM) in plastic flasks. Ahquoted cells were cryopreserved at -80 °C in 10% DMSO until use (maximum three months). Cells from 16 hCB samples were used.
Clonogenic assays and plating efficiency
Clonogenic assays were performed according to previously described methods [12] [13] [14] . Briefly, cells were plated in methylcellulose and IMDM supplemented with 30% FCS, 1% BSA, 10% conditioned medium from the bladder carcinoma cell line 5637 and 2IU of recombinant erythropoietin. Triplicate cultures were prepared with a final concentration of 1 or 2 x 10 5 MNC ml"' in four-well tissue culture plates (Falcon). The plates were incubated for 14 days at 37 °C in 5% CO2 and fully humidified air. Colonies were scored on an inverted microscope at seven days to count more differentiated progenitors (GM-CFCd7 and CFU-E) and at 14 days to count earlier progenitors (GM-CFCdl4 and BFU-E) [15] according to established criteria: GM-CFC contain at least 50 cells, a CFC-E is a group of at least five hemoglobinized cells, while BFU-E are composed of at least three clusters of hemoglobinized cells close to one another [14, 15] . Only experiments on hCB with a minimal cloning efficiency of 80 GMCFCdl4/10 5 adherent cell depleted MNC were retained for analysis. To determine whether incubation in medium affected colony formation (plating efficiency), cells from three hCB were incubated in duplicate for one hour, 24 hours or five days and their plating efficiencies compared.
Effect of ET-743 treatment schedule on hemopoietic precursors
After thawing and washing, cells were exposed to ET-743 for one hour or 24 hours at 37 °C in IMDM, then washed twice with medium before being plated on clonogenic assays. For the daily x 5 experiments, cells were incubated each day with the drug for one hour in IMDM, then washed with 10 ml medium and subsequently conserved at 37 °C in IMDM containing 10% FCS until the next exposure 23 hours later. On the fifth day cells were plated immediately after being washed. Controls were treated in the same way but without the addition of ET-743. For each schedule, a first set of three to six experiments were set up at concentrations ranging over four logs, while in a second set of three to six experiments doses were chosen within the ID30-ID90 range in order to fine-tune the dose-response curve between critical concentrations.
Assays on tumour cell lines
The effect of ET-743 treatment was evaluated by standard clonogenic assay on human tumour cell lines of different origins: IGROV-1, OVCAR-3, SW 626 derived from ovarian cancer and L0V0, L0V0/DX and SW 620 from colon cancer, A549 from lung cancer, A375 from melanoma and MCF7 from breast cancer. Exponentially growing cells were treated for one hour or 24 hours with different concentrations of ET-743. After drug treatment, control and treated cells were plated in 30 mm Petri dishes with 3 ml of fresh medium. Six independent replicates were prepared for controls and at each drug concentration. Cell viability was checked using erythrosin B. The colonies were allowed to develop for 10 days. The clonogenic potential of exponentially growing untreated cells ranged from 37%-70% of the cell types plated, and was normalised to 100%. The colonies were stained with 1% crystal violet solution in 20% ethanol, and the number of colonies and mean clone area were measured by the Entry Level image system (Immagini & Computer Italia). A background correction was made and the smallest control cell colony was taken as the minimum for establishment of the cut-off point.
Effect of incubation on progenitor cell sensitivity
To evaluate possible changes in the sensitivity of hemopoietic cells kept in culture conditions for a prolonged time (such as in the experiments with 24 hours or daily x 5 exposure), hCB cells were treated with ET-743 at concentrations near the ID70 (1 hour at 10 ng/ml and 24 hours at 2 ng/ml), either fresh or after pre-incubation in IMDM for 24 hours or five days, then washed and plated. The inverse sequence was also tested: cells were first treated with ET-743 (doses and schedules as above), then plated either immediately or after further post-incubation in medium for 24 hours or five days.
Activity of ET-743 after incubation in medium
To quantify the effect of experimental conditions on ET-743, the drug was diluted in IMDM and left for one hour and 24 hours at 37 °C, then used to treat freshly thawn hCB cells as described above.
Statistical methods
For all the outcome variables considered, tests for normality did not indicate major departures from the assumption of normal distribution, and statistical tests were performed on the basis of this assumption. To evaluate the effect of the schedule of treatment on hemopoietic precursors, their survival was expressed as a proportion of untreated controls (% surviving cells). Upon visual inspection of the doseresponse curves for all of the experiments, it was felt that a quadratic model of the observed percentage of surviving cells on the dose best approximated the dose-response relationship. Doses beyond the first one at which no surviving cells were observed were not considered for modeling so that the flat tail of the dose-response relationship was ignored. The model could be fitted by least squares only for those experiments for which at least three data points were available. The ID70 was then obtained algebraically, solving the fitted quadratic equation for the value of dose where the estimated percentage of surviving cells would equal 30%. The estimated ID70 (one for each experiment) were considered as dependent variables in an analysis of variance (ANOVA) model where each experiment (observation) was considered as an independent replicate. Appropriate binary indicators were denned to fit the main effects and interactions of the various cell types and exposure levels (one hour, 24 hours, daily x 5) and their interactions. The final model was derived by backward elimination. The squared root of the model mean squared error (Root MSE) is given as an estimate of the variability of the observations. For all other analyses a starting ANOVA model for repeated observations was used. Results are presented in terms of the estimated means, as predicted by the final model, which was also derived by backward elimination. The squared root of the estimated component of variance corresponding to the between (SDbom) observations variability is given as an estimate of the variability. For the effect of incubation duration on plating efficiency (various incubation times tested on cells from the same cord) the model included a random effect for cord and fixed effects for cell types (GM-CFCd7. GM-CFCdl4. CFC-E and BFU-E) and dura-tions of incubation (one hour, 24 hours and five days) as well as their interactions. For the effect of incubation on progenitor cell sensitivity (old or fresh cells from the same cord treated at the same dose and schedule) the model included a random effect for cord and fixed effects for cell type and cell freshness as well as their interactions. For the activity of ET743 after incubation in medium (old and fresh drug tested on the same cord) the model included a random effect for cord and fixed effects for cell type and drug freshness as well as their interactions.
Results

Effect ofET-743 treatment schedule on hemopoietic precursors
The concentrations of drug inhibiting 70% of the clonogenic cells (ID70) with each of the treatment schedules are reported in Table 1 . With all schedules, GM-CFCdl4 and BFU-E proved significantly more resistant to ET-743 than GM-CFCd7 and CFC-E (P < 0.05). Exposing cells for five times one hour or for 24 hours increased the toxicity by a factor of three to six as compared to onehour exposure (P < 0.001).
Assays on tumour cell lines
Cells from nine solid tumour lines were exposed for one hour or 24 hours to ET-743 and the corresponding effective concentrations (IC70) are reported in Table 2 . The range of IC70 at one hour and 24 hours is very wide, from 7-581 ng/ml for one-hour exposure and from 0.4-30.1 ng/ml for 24-hour exposure. Ovarian cancer cell lines appeared to be the most sensitive, while colon and lung cancer cell lines were the most resistant. Some lines (LoVo, A549, A375M, MCF7, OVAR-3) showed a higher than expected sensitivity when exposed for 24 hours, with a > 24 times higher inhibition. The sensitivity of other lines (SW620, SW626, IGROV-1, LoVo/DX) was not increased by the continuous exposure, with a colony inhibition =%24 times that of the lh treatment.
In vitro therapeutic index
The comparison between the toxicity of ET-743 on hemopoietic precursors and the cytotoxicity against tumour cell lines can be expressed as an 'in vitro therapeutic index' ( Table 2) . For all tumor cell lines except IGROV-1, the toxicity of the one-hour exposure was more pronounced on GM-CFCdl4 than on tumour cells, and the therapeutic index was thus lower than one. The therapeutic index for 24-hour exposure, on the other hand, was greater than one for five lines (A375M, MCF7, OVAR-3, SW626 and IGROV-1), three of which were of ovarian origin.
Effect of the duration of incubation on plating efficiency
The numbers of the colonies (GM-CFCd7 and dl4, CFC-E and BFU-E) obtained by plating 10 5 adherent 1D70: dose inhibiting the growth of 70% of progenitors (n = 105 observations). a P < 0.05 for GM-CFCd7 and CFC-E vs. GM-CFCdl4 and BFU-E. b P < 0.001 for 1 hour vs. 24 hours or 1 hour vs. daily x 5 exposure. Root MSE = 2.5. cell-depleted MNC after one-hour, 24-hour and five-day incubations are shown in Table 3 . For all schedules the clonogenic efficiency of more differentiated precursors (GM-CFCd7 and CFC-E) was significantly inferior to that of less differentiated precursors (GM-CFCdl4 and BFU-E) (P < 0.001). The clonogenic efficiency was lower after a 24-hour incubation than after one hour (P = 0.001), while a five-day incubation increased it (P < 0.01) for all precursors except GM-CFCdl4.
Effect of incubation on progenitor cell sensitivity
Cells pre-incubated in medium for five days are as sensitive as fresh cells to one-hour treatment, while those pre-incubated for 24 hours become significantly more resistant (P < 0.001) ( Table 4) . On the other hand, cells treated with ET-743 for one hour or 24 hours, and then post-incubated for five days in medium showed a significant reduction in their clonogenic potential (P < 0.001) (Table 5) , and the decrease was greater for a onehour than a 24-hour exposure (P = 0.008).
Activity of ET-743 after incubation in medium
When ET-743 was maintained for 24 hours at 37° in medium, its inhibitory activity on all clonogenic cells was reduced by 30% (P < 0.001) (data not shown).
Discussion
The objectives of this study were to describe the in vitro myelotoxic effect of different schedules of ET-743 and to compare it to those observed on tumour cell lines in order to extrapolate an Un vitro therapeutic index' for each schedule.
The results show that the in vitro myelotoxicity of ET-743 is schedule-dependent and increases for longer durations of exposure. Five daily one-hour exposures were three to six times more toxic than a single onehour exposure, suggesting an AUC-dependency for the myelotoxicity. The 24-hour exposure, on the other hand, was 3-6 times more toxic, suggesting that this schedule was less AUC-dependent. This observation might be biased by a variety of experimental artefacts, the identification of which was also part of the study: it was found that the activity of ET-743 was reduced by 30% after 24 hours in culture conditions; that the plating efficiency was lower after 24 hours of incubation but increased after five days of incubation; that sensitivity to ET-743 was almost halved when the cells had been pre-incubated for 24 hours in medium, while a five-day postincubation in medium resulted in a decrease of the surviving cells. From all these data, we might infer that the 24-hour treatment was less toxic than expected because ET-743 lost part of its activity during in vitro incubation, while the resistance of progenitors was increased. We could therefore speculate that the in vivo myelotoxicity of ET-743 might be more AUC dependent than has been observed in vitro.
On tumour cells, ET-743 showed important differences between different cell lines in pattern of cytotoxicity, in terms both of sensitivity and schedule-dependency, with a very favorable profile for ovarian cancer cell lines. For some tumour cell lines, the increase in efficacy of the 24 hours over that of the 1-hour exposure was larger than that observed for myelotoxicity, which translates into a better therapeutic index for the 24-hour schedule of exposure. These results confirm the preliminary data reported in cell cultures [7] , clonogenic assays of freshly explanted human tumours [16] and xenografts [5] and confirm the suggestion that, at least in some tumour types, prolonged infusion may be the best way of administering ET-743 to patients. Preliminary data from phase I trials seem to confirm this suggestion, given that the prolonged exposure schedules (24-hour infusion or one hour daily x 5) allowed the administration of higher doses compared to the single one-hour exposure [17] [18] [19] .
As already mentioned, we identified some biases which should be dealt with by researchers using clonogenic assays in preclinical hematotoxicology. The majority of published data on in vitro myelotoxicity have been generated with different durations of exposure from one-hour to continuous exposure, i.e., plating cells in semi-solid medium together with the drug to be tested [11, 20, 21] . No attention was paid to the fact that prolonged incubation of cells with a drug might produce artefacts due to the poor stability and decreased activity over time, thus resulting in treatments of different intensity according to exposure. Incubation may also modify the intrinsic properties of cells, such as plating efficiency and sensitivity to the drug, the latter of which is also affected by the sequence of prolonged incubation and treatment. Overall, it seems hazardous to draw conclu-sions regarding schedule dependency of toxicity only on the basis of in vitro studies.
Having identified some of the biases inherent to the in vitro system, we suggest that the lack of AUC-dependency of the 24-hour exposure could probably be due to some artefacts, the correction of which might further support the conclusion that the in vivo myelotoxicity of prolonged exposure and the corresponding therapeutic indexes are AUC-dependent. Even though some of the in vitro artefacts may apply to both tumor cell lines and hematopoietic tissues, we cannot exclude the possibility that other artefacts might have different effects on clonogenic and tumor cells, respectively. For the time being, xenografts remain the most reliable model for schedule dependency, while in vitro myelotoxicity tests could be useful for decreasing the number of animals treated by narrowing the range of the schedules to be tested.
An interesting finding of this study was the profound toxicity observed on cells which were incubated for five days after treatment. Although the permanence of cells in medium increased both plating efficiency and resistance to ET-743, the permanence in medium after exposure to the drug resulted in a significantly greater toxicity as compared to cells plated immediately after treatment. This observation suggests that the plating mixture has the capacity to decrease the myelotoxicity of the drug and, since the main difference between plating and incubation medium is the presence in the former of hematopoietic growth factors, it may be speculated that the toxic effect of ET-743 on hematopoietic cells is reversed by a mechanism involving hematopoietic cytokines. This hypothesis warrants further investigation.
